Similar articles

• Targeting EGFR in non-small-cell lung cancer.

  Doroshow JH. Doroshow JH. N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113. N Engl J Med. 2005. PMID: 16014890 No abstract available.
• Erlotinib in lung cancer.

  Pao W, Ladanyi M, Miller VA; Lung Cancer Oncogenome Group. Pao W, et al. N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. N Engl J Med. 2005. PMID: 16240471 No abstract available.
• Optimising therapy for EGFR-addicted NSCLC: just the start.

  Govindan R, Subramanian J. Govindan R, et al. Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285167 No abstract available.
• Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

  Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K. Nurwidya F, et al. Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Respir Investig. 2014. PMID: 24636263 Review.
• [KRAS status versus EGFR status in lung cancer therapy].

  Lacroix L, Besse B, Bidart JM, Bosq J. Lacroix L, et al. Bull Cancer. 2009 Dec;96 Suppl:S75-83. doi: 10.1684/bdc.2009.0999. Bull Cancer. 2009. PMID: 20034873 Review. French.